Pharmca Proposal to Widen Access and Change the Funded Brand of Hep B and HIV drugs

Pharmca Proposal to Widen Access and Change the Funded Brand of Hep B and HIV drugs

PHARMAC is proposing the widening of access to tenofovir disoproxil and entecavir, antiviral medicines used for the treatment of hepatitis B and HIV. These changes would have impacts that they would like your feedback on: From 1 June 2018 the Special Authority and Hospital Restrictions for both chemicals would be removed. The funded brand of […]

NZ ahead of the pack in funding revolutionary HIV-prevention drug PrEP

NZ ahead of the pack in funding revolutionary HIV-prevention drug PrEP

The New Zealand AIDS Foundation applauds PHARMAC’s decision to become one of the first countries in the world to publicly fund the HIV-prevention drug Pre-Exposure Prophylaxis (PrEP) – meaning those at high risk of HIV have another way to protect themselves. From 1 March 2018, Gilead Sciences’ drug Truvada will be available to eligible patients […]


Booking.com